The genus Hepatozoon consists of apicomplexan protozoans that affect mammals, birds, amphibians, and reptiles. In dogs, the Hepatozoon species include H. canis and H. americanum, which are transmitted by the Rhipicephalus sanguineus tick and cause nonspecific signs, such as fever, weight loss, diarrhea, and blood disorders. These protozoans have a worldwide distribution in Europe, Asia, Africa, and North and South America, including Colombia. The aim of this study was to determine the prevalence and risk factors associated with H. canis in the urban and rural areas of Ibagué, Colombia. Blood samples were collected from 308 dogs (180 rural areas and 128 urban areas). Collected data included dog breed, sex, age, environmental factors, and the presence of ectoparasites. A fragment of the 18S rRNA gene was amplified by PCR for detection of the pathogen and confirmed by sequencing. Among the 308 samples, 14 were positive (14/308, 4.5%) for the presence of H. canis. The partial sequence of the 18S rRNA gene showed identity values >98% with H. canis, forming a cluster with sequences from Latin America. An epidemiological survey found two protective factors: most of the time at home (P=0.055) and overnight stay at home (P=0.03). This is the first molecular study of the prevalence and phylogeny analysis of H. canis in Ibagué, Colombia. The findings may help determine risk factors and enhance our understanding of the geographic distribution of H. canis in Colombia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11187595 | PMC |
http://dx.doi.org/10.1292/jvms.24-0035 | DOI Listing |
Gastric Cancer
January 2025
Department of Medical Oncology, Hospital Clinico Universitario, INCLIVA, Biomedical Research Institute, University of Valencia, Avenida Menendez Pelayo nro 4 accesorio, Valencia, Spain.
Introduction: Gastric cancer (GC) burden is currently evolving with regional differences associated with complex behavioural, environmental, and genetic risk factors. The LEGACy study is a Horizon 2020-funded multi-institutional research project conducted prospectively to provide comprehensive data on the tumour biological characteristics of gastroesophageal cancer from European and LATAM countries.
Material And Methods: Treatment-naïve advanced gastroesophageal adenocarcinoma patients were prospectively recruited in seven European and LATAM countries.
Breast Cancer Res Treat
January 2025
Division of Medical Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Purpose: There is an increasing incidence of young breast cancer (YBC) patients with uncertainty surrounding the factors and patterns that are contributing.
Methods: We obtained characteristics and survival data from 206,156 YBC patients (≤ 40 years of age) diagnosed between 2005 and 2019 from the National Cancer Database (NCDB). Patients were subdivided into two comparison groups based on year of diagnosis (2005-2009, Old vs.
Am J Sports Med
January 2025
Department of Pharmacology and Biostatistics, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Background: Patellar instability is frequently encountered by orthopaedic surgeons. One of the major risk factors of this condition is underlying trochlear dysplasia (TD). Recent trends have indicated the use of multiple procedures to correct patellar instability under these conditions.
View Article and Find Full Text PDFClin Exp Nephrol
January 2025
Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-Ku, Saitama, Saitama, 330-8777, Japan.
CNS Drugs
January 2025
Department of Cardiology, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Background: Early neurological deterioration (END) is associated with a poor prognosis in acute ischemic stroke (AIS). Effectively lowering low-density lipoprotein cholesterol (LDL-C) can improve the stability of atherosclerotic plaque and reduce post-stroke inflammation, which may be an effective means to lower the incidence of END. The objective of this study was to determine the preventive effects of evolocumab on END in patients with non-cardiogenic AIS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!